zydelig
gilead sciences ireland uc - idelalisibul - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
glucothera 1,4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
glucothera 2,4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
glucothera 4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
glucothera 1,4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
glucothera 2,4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
glucothera 4 m/v glucoza
haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone
irnother concentrat pentru solutie perfuzabila 100 mg/5 ml
therdose pharma pvt. ltd. - irinotecanum - concentrat pentru solutie perfuzabila - 100 mg/5 ml
celvapan
nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccinuri - profilaxia gripei cauzate de virusul a (h1n1) v 2009. celvapan ar trebui să fie utilizate în conformitate cu recomandările oficiale.
lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, pulmonar non-celulă mică - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.